Cell-Based Vaccines Development Lab
Multidisciplinary cutting-edge technologies to develop innovative bioprocesses for vaccine production
Research Focus
iBET’s Cell-Based Vaccines Lab aims to strengthen iBET’s expertise and leadership in vaccine development nationally and internationally. We focus on advancing R&D in bioprocess engineering while also ensuring specialized training of researchers.
Our activities are centered on employing and combining process intensification, synthetic and systems biology, and enzymatic bioconjugation to enhance the production, purification and characterization of vaccine candidates against infectious diseases like COVID-19, Malaria, Influenza, and Polio.
Areas of Activity
Process intensification
Multi-stage bioreactor approach for continuous production of influenza virus-like particles (VLPs)
Synthetic and (bottom-up) systems biology
Reverse engineering using omics technologies (e.g. single cell RNA sequencing) and gene editing (e.g. CRISPR-Cas9)
Enzymatic bioconjugation
Tyrosinase-catalysed bioconjugation to produce functionalized ferritin (Ft) nanoparticles
António Roldão
Head of the Cell-based Vaccines Development Laboratory & Coordinator of Late-Stage R&D Unit
António Roldão is the head of the Cell-based Vaccines Development Lab (since 2019) and Coordinator of Late-Stage R&D Bioproduction Unit (since 2021) at iBET.
